Robecosam AG lifted its stake in shares of Bioamber Inc (NYSE:BIOA) by 82.9% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,478,000 shares of the biotechnology company’s stock after acquiring an additional 670,000 shares during the period. Robecosam AG owned approximately 2.84% of Bioamber worth $741,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Bank of New York Mellon Corp grew its position in Bioamber by 336.2% in the second quarter. Bank of New York Mellon Corp now owns 54,106 shares of the biotechnology company’s stock valued at $139,000 after purchasing an additional 41,701 shares in the last quarter. Vanguard Group Inc. grew its position in Bioamber by 9.9% in the second quarter. Vanguard Group Inc. now owns 303,360 shares of the biotechnology company’s stock valued at $780,000 after purchasing an additional 27,278 shares in the last quarter. TD Asset Management Inc. bought a new position in Bioamber in the second quarter valued at $977,000. Finally, FMR LLC grew its position in Bioamber by 18.7% in the first quarter. FMR LLC now owns 1,335,000 shares of the biotechnology company’s stock valued at $3,097,000 after purchasing an additional 210,000 shares in the last quarter. 44.42% of the stock is owned by institutional investors and hedge funds.

BIOA has been the subject of a number of analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $12.00 target price on shares of Bioamber in a research report on Wednesday, November 8th. Cowen Inc reissued a “hold” rating and issued a $1.00 price objective on shares of Bioamber in a research report on Friday, November 10th. Finally, ValuEngine downgraded shares of Bioamber from a “sell” rating to a “strong sell” rating in a research report on Tuesday, August 8th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and one has assigned a buy rating to the company. Bioamber presently has a consensus rating of “Hold” and a consensus price target of $6.50.

Bioamber Inc (NYSE:BIOA) opened at $0.45 on Friday. Bioamber Inc has a 12-month low of $0.32 and a 12-month high of $6.35. The company has a debt-to-equity ratio of 0.24, a quick ratio of 0.75 and a current ratio of 1.08.

ILLEGAL ACTIVITY WARNING: This news story was originally posted by Watch List News and is the sole property of of Watch List News. If you are reading this news story on another publication, it was illegally stolen and republished in violation of international copyright & trademark legislation. The original version of this news story can be viewed at https://www.watchlistnews.com/robecosam-ag-raises-stake-in-bioamber-inc-bioa/1727245.html.

About Bioamber

BioAmber Inc (BioAmber), formerly DNP Green Technology, Inc, is an industrial biotechnology company, which produces sustainable chemicals. The Company’s technology platform combines industrial biotechnology and chemical catalysis to convert renewable feedstocks into sustainable chemicals that are replacements for petroleum-derived chemicals, which are used in a range of everyday products, including plastics, food additives and personal care products.

Institutional Ownership by Quarter for Bioamber (NYSE:BIOA)

Receive News & Ratings for Bioamber Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioamber Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.